Yerkang Pharmaceuticals (stock code 300267.SZ) released its performance for the first half of the year, with a net profit attributable to the parent company of 37.6346 million yuan, an increase of 497.36%.

Zhtng Cijng APP News, Erkang Pharmaceutical (300267.SZ) released its 2025 interim report, with the company's operating income reaching 682 million yuan, a year-on-year increase of 9.74%. Net profit attributable to shareholders of the listed company was 37.63 million yuan, a year-on-year increase of 497.36%. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 33.01 million yuan, a year-on-year increase of 1357.97%. Basic earnings per share was 0.0182 yuan.